Table 6 Risk factors for death in patients with carbapenem-resistant K. pneumoniae bacteremia at univariate analysis

Age, years; mean, median (range)

46, 48 (28–59)

54, 54 (35–68)

0.001

male

2

3

ns

female

2

7

Acute myeloid leukemia

2 (50%)

10 (100%)

0.06

Induction/reinduction intensive chemotherapy

0

6 (60%)

0.08

Steroids

4 (100%)

10 (100%)

ns

  < 1000 neutrophils/mmc

3 (75%)

9 (90%)

ns

  < 100 neutrophils /mmc

3 (75%)

8 (80%)

ns

 with <1000 neutrophils/mmc

2.7, 2 (0–7)

10.4, 7 (0–35)

0.002

 with <100 neutrophils/mmc

2.7, 2 (0–7)

4.8, 4 (0–21)

0.01

Neutrophil recovery (>1000/mmc) within 72 h from the onset of bacteremia (n° of pts)

3 (75%)

0

0.004

CRKP rectal carrier

4 (100%)

7 (70%)

ns

 One-site colonization

2 (50%)

4 (40%)

ns

 Multiple-sites colonization

2 (50%)

3 (30%)

ns

No CRKP rectal carrier

0

3 (30%)

ns

Patients not identified as CRKP carriers at the onset of bacteremia

0

7^a (70%)

0.06

Documented source of bacteremia

2 (50%)

5 (50%)

ns

Fever of unknown origin

2 (50%)

5 (50%)

ns

 CRKP carrier

2 (50%)

2 (20%)

ns

Breakthrough bacteremia

2 (50%)

8 (80%)

ns

 occurrence within 48 h of ongoing antibiotics

0

6 (60%)

0.08

Persistent bacteremia (≥3 days)

2 (50%)

7 (70%)

ns

 days of bacteremia, mean, median (range)

2.5, 2 (1–5)

3.7, 3.5 (1–10)

0.003

Shock

2 (50%)

6 (60%)

ns

Overall adequate antibiotic therapy^b

4 (100%)

5 (50%)

ns

Initial adequate antibiotic therapy^b

4^c (100%)

2^d (20%)

0.001

Modification of the initial antibiotic therapy

2^e (20%)

7^f (70%)

ns

- with adequate antibiotic therapy^b

2

3

ns

in vitro colistin-resistant CRKP isolate

1

6

ns

in vitro colistin - and tigecycline resistant CRKP isolate

0

5

ns

in vitro colistin-, tigecyclin- and gentamycin-resistant CRKP isolate

1

5

ns